Skip to main content
Year archive

MorphoSys AG — 2019 filings

All 119 regulatory filings released by MorphoSys AG (MOR) in 2019, sourced directly from the official regulator.

119 Filings
2019 Period
2019 filings (119)
Filing Released Lang
MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA (news with additional features)
Legal Proceedings Report
2019-12-30 English
First Patient Dosed in Phase 1 Clinical Study of Tafasitamab in Firstline DLBCL (news with additional features)
Legal Proceedings Report
2019-12-27 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-12-16 English
Report Publication Announcement 2019
Report Publication Announcement
2019-12-12 English
Report Publication Announcement 2019
Report Publication Announcement
2019-12-12 English
MorphoSys AG: Corporate Calendar 2020 (news with additional features)
Report Publication Announcement
2019-12-12 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-12-11 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-12-05 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-12-03 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2019-11-29 English
Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His Departure (news with additional features)
Board/Management Information
2019-11-20 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-11-20 English
Q3 statement / Q3 financial report 2019
Interim / Quarterly Report 9M 2019
2019-11-19 German
MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis (news with additional features)
Legal Proceedings Report
2019-11-18 English
Ad hoc: MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis
Legal Proceedings Report
2019-11-18 English
MorphoSys Continues to Build Commercial Presence by Opening new U.S. Headoffice (news with additional features)
Regulatory Filings
2019-11-15 English
Results for Bimagrumab in Obesity and Type 2 Diabetes presented by MorphoSys's Partner (news with additional features)
Earnings Release Q4 2019
2019-11-11 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-11-11 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2019-11-07 English
MorphoSys to Present Data on Tafasitamab at ASH 2019 Meeting (news with additional features)
Regulatory Filings
2019-11-06 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-11-06 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2019-11-06 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2019-11-06 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2019-11-06 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2019-11-06 English
MorphoSys AG Reports Third Quarter 2019 Financial Results (news with additional features)
Earnings Release Q3 2019
2019-10-29 English
MorphoSys AG: Ad hoc: Primary Endpoint met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide compared to Lenalidomide alone
Regulatory Filings
2019-10-29 English
MorphoSys AG: MOR106 Clinical Development in Atopic Dermatitis Stopped (news with additional features)
Regulatory Filings
2019-10-28 English
MorphoSys AG: Ad hoc: MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility
Legal Proceedings Report
2019-10-28 English
Invitation to MorphoSys Q3 2019 Conference Call on October 30, 2019
Report Publication Announcement
2019-10-21 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-10-15 English
MorphoSys and I-Mab Biopharma Announce IND Clearance to Initiate Clinical Trials of MOR202/TJ202 for the Treatment of Multiple Myeloma in Mainland China (news with additional features)
Legal Proceedings Report
2019-10-14 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-10-11 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-10-11 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2019-10-09 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-10-08 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2019-09-30 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-09-30 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-09-26 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-09-23 English
MorphoSys to Present at Upcoming Investor Conferences
Regulatory Filings
2019-09-17 English
MorphoSys's Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya(R) (Guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (news with additional features)
Regulatory Filings
2019-09-16 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-09-12 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-09-10 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-09-06 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-09-04 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-08-22 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-08-22 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-08-19 English
Half-yearly financial report 2019
Interim / Quarterly Report H2 2019
2019-08-08 German
MorphoSys AG Reports Second Quarter 2019 Financial Results (news with additional features)
Earnings Release Q2 2019
2019-08-06 English
MorphoSys Discloses Biomarker to Stratify Patient Population in B-MIND Study of Tafasitamab plus Bendamustine in r/r DLBCL (news with additional features)
Regulatory Filings
2019-08-06 English
MorphoSys Announces Intention to Submit Marketing Authorization Application for Tafasitamab to European Medicines Agency (news with additional features)
Legal Proceedings Report
2019-08-06 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-08-02 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-08-02 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-07-31 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-07-29 English
Invitation to MorphoSys Q2 2019 Conference Call on August 7, 2019 (news with additional features)
Call Transcript
2019-07-25 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-07-24 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2019-07-09 English
MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology (news with additional features)
Regulatory Filings
2019-07-08 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-07-03 English
Ad hoc: MorphoSys Increases Financial Guidance for 2019 Following a Milestone Payment for Antibody Otilimab (MOR103/GSK3196165) by GSK
Earnings Release FY 2019
2019-07-03 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-06-28 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-06-26 English
Correction of a release from 24/06/2019, 20:36 CET/CEST - Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
Board/Management Information
2019-06-24 English
MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer (news with additional features)
Board/Management Information
2019-06-24 English
Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
Board/Management Information
2019-06-24 English
MorphoSys Presents Primary Analysis Data from L-MIND Study of Tafasitamab (MOR208) in combination with Lenalidomide in r/r DLBCL at ICML 2019 (news with additional features)
Regulatory Filings
2019-06-22 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-06-14 English
MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic Arthritis (news with additional features)
Regulatory Filings
2019-06-14 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-06-11 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-06-05 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-06-05 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-06-03 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-05-24 English
MorphoSys to Present at Upcoming Investor Conferences (news with additional features)
Regulatory Filings
2019-05-23 English
MorphoSys AG Reports Outcome of Annual General Meeting 2019 (news with additional features)
AGM Information
2019-05-22 English
MorphoSys AG: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity (news with additional features)
Regulatory Filings
2019-05-16 English
MorphoSys AG: Ad hoc: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity
Regulatory Filings
2019-05-16 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-05-14 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-05-09 English
Q1 statement / Q1 financial report 2019
Interim / Quarterly Report Q1 2019
2019-05-09 English
MorphoSys AG Reports First Quarter 2019 Results (news with additional features)
Earnings Release Q1 2019
2019-05-07 English
Invitation to MorphoSys Q1 2019 Conference Call on May 8, 2019
Report Publication Announcement
2019-05-02 English
MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple Myeloma (news with additional features)
Legal Proceedings Report
2019-04-29 English
MorphoSys and Galapagos Announce Initiation of GECKO Phase 2 Study with MOR106 in Atopic Dermatitis Patients (news with additional features)
Environmental & Social Information
2019-04-23 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-04-23 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2019-04-16 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2019-04-16 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2019-04-16 English
MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Familial Adenomatous Polyposis (news with additional features)
Regulatory Filings
2019-04-15 English
MorphoSys Nominates New Candidate for Supervisory Board (news with additional features)
AGM Information
2019-04-10 English
MorphoSys AG: Bekanntmachung der Einberufung zur Hauptversammlung am 22.05.2019 in Planegg mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information
2019-04-10 German
MorphoSys to Present at Upcoming Investor Conferences
Report Publication Announcement
2019-04-09 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2019-04-05 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2019-04-05 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2019-04-05 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2019-04-05 English
Dr. Sarah Fakih joins MorphoSys as Head of Corporate Communications and Investor Relations (news with additional features)
Board/Management Information
2019-04-01 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-03-27 English
MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma (news with additional features)
Regulatory Filings
2019-03-19 English
Annual financial report 2018
Annual Report FY 2018
2019-03-19 German
MorphoSys Presents Results for Fiscal Year 2018 (news with additional features)
Earnings Release FY 2018
2019-03-13 English
MorphoSys AG: MorphoSys Provides Updates on L-MIND and B-MIND Clinical Trials of MOR208 in Relapsed/Refractory DLBCL (news with additional features)
Regulatory Filings
2019-03-07 English
Invitation to Year-End Results 2018 Conference Call of MorphoSys AG on March 14, 2019
Report Publication Announcement
2019-03-04 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-02-27 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-02-27 English
MorphoSys to Present at Upcoming Investor Conference
Regulatory Filings
2019-02-21 English
Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire (news with additional features)
Board/Management Information
2019-02-19 English
Ad hoc: Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire
Board/Management Information
2019-02-19 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-02-14 English
MorphoSys Announces Appointment of David Trexler as President and Member of the Board of Directors of MorphoSys US Inc. (news with additional features)
Board/Management Information
2019-02-05 English
MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab (news with additional features)
Legal Proceedings Report
2019-01-31 English
Ad hoc: MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
Legal Proceedings Report
2019-01-26 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-01-23 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-01-23 English
MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Ulcerative Colitis (news with additional features)
Regulatory Filings
2019-01-17 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2019-01-17 English